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Trodusquemine enhances Aβ42 aggregation but
suppresses its toxicity by displacing oligomers from
cell membranes
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Transient oligomeric species formed during the aggregation process of the 42-residue form
of the amyloid-β peptide (Aβ42) are key pathogenic agents in Alzheimer’s disease (AD). To
investigate the relationship between Aβ42 aggregation and its cytotoxicity and the influence
of a potential drug on both phenomena, we have studied the effects of trodusquemine. This
aminosterol enhances the rate of aggregation by promoting monomer-dependent secondary
nucleation, but significantly reduces the toxicity of the resulting oligomers to neuroblastoma
cells by inhibiting their binding to the cellular membranes. When administered to a C. elegans
model of AD, we again observe an increase in aggregate formation alongside the suppression
of Aβ42-induced toxicity. In addition to oligomer displacement, the reduced toxicity could also
point towards an increased rate of conversion of oligomers to less toxic fibrils. The ability of a
small molecule to reduce the toxicity of oligomeric species represents a potential therapeutic
strategy against AD.
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A lzheimer’s disease (AD) is a fatal neurodegenerative dis-order characterized by aberrant protein aggregation,which results in multifactorial neuronal dysfunction
affecting synaptic signaling, mitochondrial function, neuroin-
flammation and neuronal loss1–6. Although the pathophysiology
of AD is extremely complex and heterogeneous, the buildup of
amyloid plaques in the extracellular space of the brain par-
enchyma is a hallmark of this disease. These proteinaceous
deposits form as a consequence of the aggregation of the intrin-
sically disordered amyloid-β peptide (Aβ), a proteolytically
derived transmembrane fragment of the amyloid precursor pro-
tein (APP), and a multitude of biochemical, genetic and animal
investigations point to the aberrant behaviour of this molecule as
central to the aetiology of AD1–5,7.
A range of small molecules and antibodies have been char-
acterized for their ability to modulate the self-assembly process of
the Aβ peptide8–12. So far, however, no clinical trial based on such
compounds has been successful13. This situation can be attributed
in part to the limited understanding of the mechanisms by which
aggregation occurs and of the means by which these compounds
modify the aggregation process, and also to their administration
at too late a stage in a clinical situation where the amyloid load
has already reached significant levels9. To address this challenge,
we have developed a rational drug discovery strategy based on
chemical kinetics to elucidate, in molecular detail, the effects of
candidate compounds on the microscopic processes, in particular
primary and secondary nucleation and elongation, that underlie
the aggregation phenomenon8,9,14. The 42-residue form of the Aβ
peptide (Aβ42) is a primary component of the amyloid deposits in
AD, and we have found that both small and large molecules
can alter, often dramatically, one or more of these specific
steps8,9,15,16.
Increasing evidence indicates that oligomeric species of Aβ42
formed as intermediates during the aggregation process are
substantially more toxic to neuronal cells than are the mature
fibrils or plaques, and therefore are likely to contribute very sig-
nificantly to the onset and spread of disease5,7,17. In addition, it
has been shown that molecular chaperones and antibodies can
reduce the levels or degree of toxicity of such oligomeric
intermediates15,18,19. Therefore, other molecules with similar
behaviour could be efficacious as therapeutic agents to combat
AD by targeting the most deleterious species associated with Aβ42
aggregation. In the present study, we investigate the effects of the
aminosterol trodusquemine (also known as MSI-1436), a natural
product that was first isolated from the liver of the dogfish
shark20, on the aggregation of Aβ42.
Trodusquemine belongs to a family of compounds shown to
displace proteins from membranes, a feature proposed to preserve
membrane integrity21. Indeed, trodusquemine and the closely
related aminosterol squalamine have been shown to inhibit α-
synuclein aggregation and its related toxicity by displacing both
monomers and oligomers from the membranes of cultured
neuroblastoma cells, and also to suppress the onset of paralysis in
a C. elegansmodel of Parkinson’s disease22,23. As drug candidates,
aminosterols have a well-characterized pharmacokinetic activity,
and high tolerability and safety profiles in humans, as a result of
several past and ongoing clinical trials, and at least one (tro-
dusquemine) has been reported to be able to cross the
blood–brain barrier24–26. We show that despite enhancing the
rate of Aβ42 aggregation in vitro by accelerating the microscopic
step of secondary nucleation, trodusquemine ameliorates the
toxicity of Aβ42 oligomers in neuroblastoma cells by reducing
their binding affinity to cellular membranes, and also decreases
the toxicity inherent to Aβ42 aggregation in a C. elegans model of
AD when administered before or during the manifestation of a
toxic phenotype.
Results
Effects of trodusquemine on Aβ42 aggregation. Trodusquemine
consists of a fused sterol ring covalently bound to the polyamine
spermine (Fig. 1a)25. Polyamines are small cationic molecules
that have been found to increase the rate of Aβ40 aggregation
in vitro27; although, the mechanism by which this process takes
place has yet to be elucidated. Initially, we followed Aβ42 fibril
formation in vitro using the well-defined thioflavin-T (ThT)-
based chemical kinetics assay28. We monitored the aggregation of
monomeric Aβ42 at a concentration of 2 µM in 20 mM sodium
phosphate, 200 µM EDTA, pH 8.0, 37 °C, under quiescent con-
ditions, in the absence and presence of trodusquemine at ratios of
Aβ42-to-trodusquemine of 10:1, 5:1 and 1:1 molar equivalents
(Fig. 1b). The results revealed that in the presence of this com-
pound, the half-time of Aβ42 aggregation was reduced in a dose-
dependent manner, and by a factor of two in the presence of a 5:1
ratio of Aβ42-to-trodusquemine. A similar, dose-dependent,
accelerating effect has been observed with poly-L-lysine, in which
case a factor of two reduction in the half-time of Aβ42 aggregation
was observed at a 1:10 molar ratio of Aβ42-to-lysine29.
To probe the mechanism of association between trodusque-
mine and Aβ42 and to assess the importance of the side chain of
trodusquemine in the promotion of fibril formation, we next
monitored the aggregation of Aβ42 in the presence of spermine.
We observed that this cationic polyamine accelerates the Aβ42
aggregation reaction in a dose-dependent manner (Supplemen-
tary Figure 1); however, the covalent linkage of spermine to the
sterol ring appears to increase the efficacy of trodusquemine
above that of spermine alone. The accelerative effects of spermine
and trodusquemine were further investigated at physiological
ionic strength (5 mM sodium phosphate, 150 mM NaCl, 200 µM
EDTA, pH 8.0) where electrostatic interactions between opposing
charges are weakened30. We observed that the ability of spermine
to enhance the aggregation reaction was diminished with
increasing concentrations of salt. Conversely, the accelerative
effects of trodusquemine were maintained at physiological ionic
strength (Supplementary Figure 1). Additional factors other than
electrostatic interactions between the spermine moiety and
negatively charged residues of Aβ42 are therefore likely to
contribute to the acceleration of aggregation by trodusquemine;
for example, hydrophobic interactions made possible by its sterol
ring may provide a molecular basis for its increased potency in
comparison to spermine alone.
Next, we assessed the effects of trodusquemine on secondary
processes by monitoring the aggregation kinetics of Aβ42 in the
presence of pre-formed fibrils, which act as seeds to promote
aggregate growth and multiplication. The aggregation of Aβ42
under these conditions was found, as in previous experiments, to
experience an efficient positive feedback loop as fibril surfaces act
as catalytic sites for secondary nucleation. This phenomenon,
therefore, gives rise to greatly enhanced conversion of soluble
monomeric Aβ42 into oligomeric species that are then able to
elongate to form new fibrils, as surface induced secondary
nucleation has been shown previously to dominate the in vitro
aggregation reaction of Aβ42 once primary nucleation has
generated a low but critical concentration of the total Aβ42
aggregates31. The addition of seed fibrils at the beginning of the
aggregation reaction, therefore, is able to increase the rate of fibril
formation by promoting secondary nucleation (with rate constant
k2) and elongation (with rate constant k+); under these
conditions, primary nucleation (with rate constant kn) is no
longer rate-limiting and of negligible significance in driving the
rate of Aβ42 fibril formation8,31,32. We followed the aggregation of
2 µM monomeric Aβ42 in the presence of 5% seed fibrils
(monomer equivalents, prepared as previously described9) and
trodusquemine at ratios of Aβ42-to-trodusquemine of 10:1, 5:1
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07699-5
2 NATURE COMMUNICATIONS |          (2019) 10:225 | https://doi.org/10.1038/s41467-018-07699-5 | www.nature.com/naturecommunications
and 1:1 (Fig. 1c). As observed in the unseeded reactions, the half-
time of Aβ42 aggregation decreased with increasing concentra-
tions of trodusquemine in a well-defined dose-dependent
manner. As primary nucleation is not rate-limiting in this seeded
aggregation assay, these results indicate that the enhanced
aggregation of Aβ42 in the presence of trodusquemine is not
associated with changes in the primary nucleation step.
Additional experiments were carried out in the presence of
higher levels of seed fibrils, where elongation of the pre-formed
fibrils has been found to be the dominant process of aggregate
growth; under these conditions, neither primary nor secondary
nucleation processes are rate-limiting31. We found that the rate of
aggregation of 2 µM monomeric Aβ42 in the presence of 25% of
seed fibrils and of trodusquemine at ratios of Aβ42-to-trodusque-
mine of 10:1, 5:1 and 1:1 was increased only at the highest ratio
(i.e. 1 molar equivalent) of the compound to Aβ42, and then only
slightly (the half-time was reduced from 0.28 to 0.19 h) (Fig. 1d),
confirming that trodusquemine exerts only a minimal effect on
the rate of Aβ42 elongation. Collectively, the unseeded and seeded
macroscopic aggregation experiments (Fig. 1e), therefore,
strongly suggest that the enhanced aggregation of Aβ42 in the
presence of trodusquemine is the result of an increased rate of
surface-catalyzed secondary nucleation.
We then carried out a quantitative analysis of the effects of
trodusquemine on Aβ42 aggregation by comparing the experi-
mental kinetic data from the unseeded and seeded aggregation
experiments with kinetic curves obtained by solving analytically
the rate laws of aggregation kinetics, as described in detail
previously31,33,34. This methodology enables the macroscopic
time-dependent proliferation of aggregates to be expressed as a
function of the rate constants for each of the contributing
microscopic processes. In the presence of trodusquemine, the
aggregation profiles were analyzed by introducing perturbations
of the microscopic constants into the rate laws, in order to
identify the effects on the specific processes that are affected9,14.
Using this approach, we observed that the unseeded kinetic data
in the presence of different concentrations of trodusquemine
(Fig. 1b) were very well-described by an increase in the product of
the rate constants involving secondary pathways (k+k2) (Fig. 1f);
moreover, the seeded aggregation data (Fig. 1c) were found to fit
closely to a situation where the observed increase in rate
constants can be attributed to an increase in the rate of
monomer-dependent secondary nucleation. By contrast, analyz-
ing the data for an effect on the rates of primary nucleation
failed to recapitulate the observed effects of trodusquemine on
the aggregation reaction (see Supplementary Note 1, Supplemen-
tary Figure 2).
We also examined the interaction of trodusquemine with
monomeric Aβ42 using 1H-15N-HSQC nuclear magnetic resonance
(NMR) spectroscopy at 5 °C with 50 µM uniformly 15N-labeled
Aβ42 and 50 µM trodusquemine in 5mM sodium phosphate at pH
7.4. The presence of trodusquemine did not significantly perturb
the observed amide cross-peak positions or intensities (Supple-
mentary Figure 3, Supplementary Table 1), indicating that its
binding to monomeric Aβ42 in the aggregation reaction is very
weak at the molar ratios investigated in the kinetic experiments.
Nonetheless, it is possible that even weak interactions of
trodusquemine with monomeric Aβ42 could potentially promote
its binding to fibrils, or that trodusquemine may stabilize
oligomeric species; either of these situations could be related to
the observed enhancement in the rate of nucleation by
trodusquemine. Taken together, therefore, all these experiments
indicate that trodusquemine is able to enhance significantly the
rate of secondary nucleation of Aβ42.
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Fig. 1 Trodusquemine enhances the overall rate of Aβ42 aggregation by promoting secondary nucleation. a Structure of trodusquemine (TRO). Kinetic
profiles of the aggregation of 2 µMAβ42 in the absence (black) or presence of trodusquemine at ratios of Aβ42-to-trodusquemine of 10:1, 5:1 and 1:1 (light to
dark blue) in the absence of seeds (b), in the presence of 5% seeds (c) and in the presence of 25% seeds (d). Solid lines indicate theoretical predictions
based on kinetic fitting (see Results); the data are very well-described by varying the rates associated with the presence of trodusquemine in the secondary
pathway (k+k2) (b), or associated with monomer-dependent secondary nucleation (k2) (c). e Change of the half-time of aggregation of Aβ42 as seen from
b to d. f Dependency of the apparent reaction rate constants of secondary pathways (k+k2app) on increasing concentrations of trodusquemine relative to
the condition in the absence of the molecule (k+k2). The schematic depicts the microscopic steps involved in Aβ42 aggregation. In all panels, error bars
indicate standard error of the mean (s.e.m.) of three replicates
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Statistical analysis of Aβ42 fibril size and morphology. In order
to examine independently the conclusions drawn from the
experiments using chemical kinetics and to understand in more
detail the observed increase in the ThT fluorescence intensity
with increasing concentrations of trodusquemine (Supplementary
Figure 4), we carried out a statistical analysis of fibril morphology
by means of high-resolution and phase controlled atomic force
microscopy (AFM)35,36 and transmission electron microscopy
(TEM). Aliquots of the different samples were deposited, either
on atomically flat and positively functionalized mica surfaces for
AFM or on carbon coated copper grids for TEM, at the initiation
stage (t= 0 h) and in the plateau region (t= 4 h) of the aggre-
gation reaction of monomeric Aβ42 at a concentration of 2 µM in
the absence and presence of an equimolar ratio of Aβ42-to-tro-
dusquemine (Fig. 2a–d, Supplementary Figure 5).
We first analyzed the lengths (Fig. 2e) and cross-sectional
heights (Fig. 2f, Supplementary Figure 6) of the individual fibrils
that were measured by means of high-resolution and phase
controlled AFM, which facilitates a precise morphological
comparison of aggregates across samples and minimizes the
effects of sample deformation (<10%) by maintaining a regime of
low tip-sample interaction (see Methods for details)35,36. We then
measured the widths of the individual fibrils that were imaged by
TEM (Fig. 2g), which, in combination with the three-dimensional
AFM maps, enabled us to understand in greater detail the
structural properties of the fibrils. Incubation of Aβ42 in the
absence of trodusquemine produced fibrils with an average height
of 4.2 ± 0.2 nm (mean ± total error, see Methods for details; n=
387), a width of 12 ± 1 nm (n= 200) and a length of 1.81 ±
0.12 µm (n= 100), while in the presence of an equimolar ratio of
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Aβ42-to-trodusquemine, the fibrils had an average height of 6.3 ±
0.3 nm (n= 174), a width of 15 ± 1 nm (n= 200) and a length of
0.63 ± 0.06 µm (n= 100) (Fig. 2e–g).
Both techniques indicate that the incubation of Aβ42 in the
presence of trodusquemine resulted in the formation of fibrils
characterized by larger cross-sectional dimensions, as observed by
the increased average height (Fig. 2f) and width (Fig. 2g), in
comparison to fibrils formed in the absence of the molecule (see
Supplementary Note 2 for an AFM and TEM size comparison).
The comparison of the length distributions of the two types of
fibrillar aggregates measured with AFM showed that fibrils
formed in the presence of trodusquemine were markedly shorter
than fibrils formed in their absence (Fig. 2e); this phenomenon
was particularly evident in the TEM images (Fig. 2d). An increase
in the frequency of nucleation events is expected to result in the
formation of shorter fibrils. Indeed, in a system dominated by
secondary nucleation, the average fibril length is expected to scale
with37
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
kþ=k2
 q
: ð1Þ
Hence, the measured increase of the rate constant for
secondary nucleation, k2, by a factor of 5 in the presence of
equimolar concentrations of Aβ42-to-trodusquemine (Fig. 1f) is
predicted to result in a decrease of the average fibril length by a
factor of 1/√(5) ≈ 0.5. This prediction is consistent with the
experimentally observed average length that is reduced by a factor
of ≈0.4 (Fig. 2e), adding further support to the conclusions of the
analysis of the chemical kinetics experiments that surface-
catalyzed secondary nucleation is enhanced by trodusquemine.
Moreover, TEM measurements after 1 h of aggregation demon-
strated that the presence of trodusquemine led to the production
of numerous epicenters of increased nucleation, as evidenced by
the significantly increased formation of localized short fibrils in
groups (see Supplementary Note 3, Supplementary Figure 7).
Collectively, therefore, all the results reported in this paper
demonstrate that trodusquemine utilizes the surface of pre-
formed fibrils of Aβ42 to nucleate rapidly via secondary
nucleation to generate a multitude of short fibrils.
Trodusquemine reduces Aβ42 oligomer toxicity to cells. The Aβ
oligomers that form during an ongoing aggregation process reach
a maximum of ca. 1% of the total monomer concentration at the
point in time where ca. half the monomers are converted to
fibrils31. Many studies have therefore used methods to produce
and stabilize oligomers formed at higher concentrations in order
to make it possible to study the properties of such species in
detail38,39. Adhering to such practice, we next measured the
effects of trodusquemine on the toxicity of Aβ42 oligomers by
means of Aβ-derived diffusible ligands (ADDLs). These small and
soluble aggregates (referred to hereafter as Aβ42 oligomers) are a
frequently employed oligomeric model and have been found to
accumulate in the brains of Alzheimer’s disease patients, as
shown by conformation-sensitive antibodies raised against
them40, and are capable of causing neurological damage,
attenuating mitochondrial activity, increasing membrane per-
meability, promoting the production of reactive oxygen species
(ROS), inhibiting long-term potentiation (LTP) and causing
abnormal synapse composition, shape, and density40–44.
Aβ42 oligomers were generated as previously described41 from
both recombinant and synthetic peptides (see Supplementary
Note 4) and added to the cell culture media of human
neuroblastoma SH-SY5Y cell lines at the same concentration
(monomer equivalents). Following the observation that the two
oligomer forms reduced the viability of the cells to similar extents
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) reduction assay (Supplementary Figure 8), we
decided to use the synthetic Aβ42 oligomers for further studies.
The structural characteristics of these Aβ42 oligomers was
investigated by western blot and dot blot assay using a
conformation-sensitive anti-ADDLs antibody (Supplementary
Figure 9) and found to be in good agreement with previous
reports41.
The Aβ42 oligomers were added to cell culture media at a
concentration of 1 µM (monomer equivalents) and the viability of
neuroblastoma SH-SY5Y cells was found to be reduced by 24 ± 3%
(all cell biology results are described by mean ± s.e.m. of three-
independent experiments), as measured by their ability to reduce
MTT (Fig. 3a). The Aβ42 oligomers were then incubated for 1 h at
37 °C at a concentration of 1 µM (monomer equivalents) in the
absence or presence of different concentrations of trodusquemine
(from 0.1 to 1.0 µM) and subsequently added to the cell culture
medium for 24 h. Trodusquemine was found to decrease the
toxicity of the oligomers significantly, such that at a 1:1 ratio of
Aβ42-to-trodusquemine, cell viability was increased by 22 ± 2%, up
to 96 ± 2% relative to untreated cells (Fig. 3a), a value approximately
equal to that of cells treated with 1 µM trodusquemine in the
absence of oligomers (97 ± 1% of untreated cells). The Aβ42
oligomers also caused a significant increase in ROS levels in
SH-SY5Y cells (328 ± 14% of the value for untreated cells) (Fig. 3b),
as monitored by the fluorescent probe 2′,7′-dichlorodihydrofluor-
escein diacetate (CM-H2DCFDA), in agreement with previous
observations43. The level of ROS-derived fluorescence was observed
to decrease substantially when the oligomers were co-incubated
with 1 µM trodusquemine (163 ± 15%), to a level similar to that of
cells treated with cell culture medium (100 ± 12%) or 1 µM
trodusquemine alone (119 ± 6%, Fig. 3b).
To explore further the mechanism of the reduction of
oligomer-induced toxicity by trodusquemine, we monitored the
interaction of the Aβ42 oligomers with SH-SY5Y cellular
membranes in the absence and in the presence of trodusquemine
using confocal microscopy. The cells were incubated with
oligomers (1 μMmonomer equivalents) for 15 min in the absence
or presence of 1 µM trodusquemine and images were scanned at
the apical planes. The oligomers and the membranes were
visualized by staining with the sequence-specific 6E10 anti-Aβ
antibody followed by the Alexa Fluor 488-conjugated secondary
antibody (green channel) and the Alexa Fluor 633-conjugated
wheat germ agglutinin (red channel), respectively. Large numbers
of oligomers were observed to be bound to the cell membranes in
the absence of trodusquemine45, whereas in its presence the
extent of binding to the cellular membranes was reduced by more
than 75% (Fig. 3c). As previous work has shown that toxicity
monitored by the MTT reduction assay and ROS production
correlates directly with the extent of the interaction of the
oligomers with cell membranes22,46, this finding is consistent with
the greatly reduced toxicity of Aβ42 aggregates in the presence of
trodusquemine.
As a control, we monitored the co-localization of Aβ42
oligomers with lysosomes using HiLyte Fluor 647-labeled Aβ42
and the LysoTracker probe (Supplementary Figure 10). We
observed negligible activation of lysosomes in cells exposed to
oligomers and minimal co-localization of the Aβ42 oligomers with
lysosomes after 15 min of treatment. To ensure further that the
oligomers observed were bound to the membranes (Fig. 3c) and
not lysosomal, we also analyzed the median planes of the cells
(Supplementary Figure 11). Intracellular green fluorescence
resulting from the oligomers was not observed in these planes,
indicating strongly that the total fluorescence observed in all
planes arises only from the oligomers bound to the membranes.
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In an additional set of experiments, we monitored the effects of
trodusquemine when administered to cells as a pre-treatment
prior to their exposure to toxic oligomers formed in the absence
of the molecule. Cells were incubated with trodusquemine for 15
min and subsequently washed to remove any unbound molecules.
Aβ42 oligomers were then administered at an equimolar
concentration under the conditions described previously above,
and a marked decrease in the toxicity of the oligomers was
observed, as monitored by cell viability (94 ± 3% of untreated
cells, Fig. 3a) and ROS production (197 ± 10% of untreated cells,
Fig. 3b). A prominent decrease in oligomer binding to the cellular
membrane was also observed (33 ± 3% of treated cells, Fig. 3c).
Indeed, the MTT reduction, ROS levels and oligomer binding
measurements for pre-treated cells are highly similar to those
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Fig. 3 The toxicity of Aβ42 oligomers is reduced by trodusquemine. a Effects of trodusquemine on the Aβ42 oligomer-induced decrease of MTT reduction.
Oligomers (1 µM) were incubated in the absence or presence of 10:1–1:1 ratios of Aβ42-to-trodusquemine (blue bars) for 1 h at 37 °C and incubated with
cells for 24 h. Cells were also treated with corresponding concentrations of pre-incubated trodusquemine (white bars), or pre-treated with 1 µM
trodusquemine, washed and exposed to oligomers under the same conditions (red bar). Samples containing oligomers were analyzed by one-way ANOVA
followed by Bonferroni’s multiple comparison test relative to untreated cells (***P < 0.001) and cells treated with oligomers (open circles, °°P < 0.01, °°°P <
0.001). A total of 80,000–100,000 cells were analyzed per condition in total. b Effects of trodusquemine on Aβ42 oligomer-induced ROS production.
Oligomers (1 µM) were incubated with cells for 15 min in the absence or presence of 1 µM trodusquemine. Cells were also treated with 1 µM
trodusquemine. The green fluorescence arises from the CM-H2DCFDA probe. The corresponding semi-quantitative values of the green fluorescence
signals are shown. The red bar indicates the conditions shown in a. Scale bars, 30 µm. Samples containing oligomers were analyzed by one-way ANOVA
followed by Bonferroni’s multiple comparison test relative to untreated cells (*P < 0.05, **P < 0.01, ***P < 0.001) and cells treated with oligomers (°°°P <
0.001). A total of 100–120 cells were analyzed per condition in total. c Representative confocal scanning microscopy images of the apical sections of cells
treated for 15 min with oligomers (1 µM) in the absence or presence of 1 µM trodusquemine. Red and green fluorescence indicate the cell membranes and
the oligomers, respectively. The histogram shows the percentage of co-localization. The red bar indicates the conditions shown in a. Scale bars, 10 µm.
Samples containing oligomers were analyzed by one-way ANOVA followed by Bonferroni’s multiple comparison test relative to untreated cells (*P < 0.05,
***P < 0.001) and cells treated with oligomers (°°°P < 0.001). A total of 50–60 cells were analyzed per condition in total. In all panels, data represent mean
± s.e.m. of three independent experiments
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described above for cells co-incubated with oligomers and
trodusquemine.
Trodusquemine modifies the properties of Aβ42 oligomers.
Several studies have demonstrated that the extent of exposure of
hydrophobic patches and aggregate size are structural determi-
nants of oligomer toxicity, with a high level of hydrophobicity
and small size associated with the ability to cause cellular
dysfunction5,19,47–50. We therefore probed these two parameters
following the interaction of the Aβ42 oligomers with trodusque-
mine. The degree of hydrophobicity of the oligomers was eval-
uated using the fluorescent dye 8-anilino-1-naphthalenesulfonate
(ANS), which binds to hydrophobic patches on the surfaces of
solvent-exposed protein aggregates51. A total of 15 µM ANS was
added to 5 µMAβ42 oligomers (monomer equivalents) after
incubation for 1 h at 20 °C in the absence or presence of between
10:1 and 1:10 molar ratios of Aβ42-to-trodusquemine (Fig. 4a).
We observed that the ANS fluorescence intensity increased in a
well-defined dose-dependent manner, indicating that trodusque-
mine interacts with the Aβ42 oligomers and that the solvent-
exposed hydrophobicity of the oligomers increases with increas-
ing levels of trodusquemine.
We next assessed the effect of trodusquemine on the size of the
aggregates using static light scattering. Following the introduction
of increasing concentrations of trodusquemine in the same ratios
as those used in the ANS measurements, enhanced light
scattering was observed with increasing concentrations of
trodusquemine (Fig. 4b), providing further evidence of an
interaction between trodusquemine and Aβ42 oligomers. More-
over, our results indicate that trodusquemine interacts more
strongly with aggregated Aβ42 (Fig. 4) than with the monomeric
species (Supplementary Figure 3), and that this interaction
changes the physicochemical properties of the aggregates. This
phenomenon is in agreement with previous data reported in the
literature for other oligomeric systems, where an increase in size
was found to be concomitant with an increase in
hydrophobicity48,52. The increases in size and hydrophobicity
caused by trodusquemine were found to be significantly higher
only at super-stoichiometric concentrations relative to the
oligomers; however, sub-stoichiometric or equimolar concentra-
tions were sufficient to impart a protective effect of
trodusquemine (Fig. 3). Indeed, at a 1:1 molar ratio, trodusque-
mine suppresses significantly the oligomer toxicity, but the
increase in both size and hydrophobicity of the oligomers is small.
It is unlikely, therefore, that the only mechanism of action
through which trodusquemine reduces the toxicity of Aβ42
oligomers is related to a substantial change of their hydro-
phobicity and size.
Increased aggregation but reduced toxicity in AD worms. To
characterize the effects of trodusquemine in vivo, we made use of
a transgenic C. elegans model of AD, in which human Aβ42 is
overexpressed in muscle tissue53. These animals, referred to
hereafter as AD worms, have a phenotypic dysfunction in their
ability to undergo body bends, commonly measured as the
thrashing frequency or motility, in units of bends per minute
(BPM), and the resultant reduced motility has been shown to be
proportional to the levels of toxic species generated during the
aggregation of Aβ42 into fibrils8. We first sought to assess the
levels of Aβ42 aggregation by staining the worms with NIAD-4, a
dye that is specific for amyloid fibrils8, in AD worms with and
without the administration of trodusquemine starting from the L4
larval stage of development prior to adulthood. Aggregation was
observed in the AD worms by monitoring the level of fluores-
cence that results from the interaction of NIAD-4 with amyloid
inclusions, and in the presence of trodusquemine, the levels of
staining increased significantly and progressively (Fig. 5a).
Indeed, at day 6 of adulthood (D6), 20 µM trodusquemine
increased the measured levels of aggregates by more than six
times in comparison to untreated AD worms.
At specific time points during their adult lifespan, the worms
were monitored in a highly sensitive manner using the Wide
Field-of-View Nematode Tracking Platform22,54. The overall
fitness of each experimental group of worms was measured
according to three characteristics after the administration of
trodusquemine at the L4 stage of development, namely body bend
frequency, speed of swimming and the extent of paralysis (Fig. 5b,
Supplementary Figure 12). All these characteristics were moved
significantly towards the behaviour of the control worms as a
result of the administration of both 10 µM and 20 µM
trodusquemine (Fig. 5b). To illustrate this point, the parameters
were summed to generate a fitness score, which reflects the overall
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animal health; trodusquemine promoted the recovery of worms
when administered at the L4 stage of development (Supplemen-
tary Movies 1 and 2), and worms treated with 20 µM
trodusquemine were shown to be approximately as healthy as
wild-type control worms (Fig. 5b).
Treatment with trodusquemine did not alter the total levels of
Aβ42 in the AD worms (Fig. 5c, Supplementary Figure 13), which
supports the conclusion that the beneficial effects of trodusque-
mine are not related to changes in Aβ42 accumulation. We then
considered the dependency of the fitness scores, the extent of
aggregated Aβ42 and the total levels of Aβ42 on the concentrations
of trodusquemine administered to the AD worms, for which a
clear correlation between the extent of aggregation and worm
health was observed (Fig. 5d), suggesting that these processes are
related. As a control, trodusquemine was administered under the
same conditions to wild-type worms (N2 strain) not expressing
Aβ42 (Supplementary Movies 3 and 4), and no improvement to
body bend frequency or speed of swimming was observed. A
minor decrease in paralysis was, however, observed (Supplemen-
tary Figure 14), suggesting that the increase in lifespan in the Aβ42
expressing worms may include a modest contribution from
changes in non-specific pathways regulating autophagy or other
apparatuses of the proteostasis network. Indeed, trodusquemine
has recently been identified as being capable of promoting
regeneration in various tissues of zebrafish and mice55 and
longevity in wild type and Parkinson’s disease worm models23.
In an additional set of experiments, AD worms displaying a
toxic phenotype (i.e. reduced body bend frequency) after
incubation under standard conditions were treated at D6 with a
20 µM dose of trodusquemine to assess the ability of the molecule
to stimulate the recovery of such worms. Indeed, the treatment-
induced positive effects on the frequency of body bends, the speed
of swimming and the extent of paralysis at late-stages in the
worm lifespan (Fig. 5e). Overall, the fitness score of the treated
AD worms was increased by 50% relative to untreated worms, as
indicated by the average change in fitness across all time points
measured in the lifespan of the worms (Supplementary Figure 12).
As a control, no detectable enhancement of the fitness readouts
was observed upon the treatment of wild-type worms (not
expressing Aβ42) with the addition of 20 µM trodusquemine at
D6 of their lives (Fig. 5e).
Collectively, these results demonstrate that trodusquemine
reduces the toxicity related to Aβ42 aggregation in AD worms at
the same time as it generates an increase in the rate of amyloid
formation (Fig. 5). We showed previously that designed
antibodies can cause comparable effects on toxicity in AD worms
by reducing significantly the quantity of aggregated Aβ42 when
administered under similar early and late treatment paradigms18.
The observed decreases in toxicity in both cases are highly likely
to be related to changes in Aβ42 oligomer behaviour, where the
antibodies dramatically reduce the rate of their formation and
trodusquemine both hastens their conversion to the mature
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amyloid state and markedly attenuates their affinity for cell
membranes.
Discussion
The identification of oligomers as the species of Aβ42 aggregates
most capable of causing cellular toxicity has resulted in an
increased focus on these aggregates as the key pathogenic agents
in AD1,5,7,17. Such aggregates of Aβ42 exist in a complex and
dynamical heterogeneous mixture, and include metastable oli-
gomers of various morphologies2,17,31. We have, therefore, sought
to provide quantitative grounds to assess the nature and origin of
the various toxic aggregates of Aβ42 by using trodusquemine to
modulate the behaviour of the aggregated species.
We first determined the rates of the various microscopic steps
associated with the aggregation of Aβ42 in the presence of tro-
dusquemine. The results show that this compound enhances the
overall process of aggregation, predominantly by increasing the
rate of the monomer-dependent secondary nucleation. The
mechanism by which the rate of secondary nucleation is increased
in the presence of trodusquemine could be related to a change in
the affinity of the monomers for fibrils after trodusquemine binds
to their surfaces; indeed, aminosterols have been shown pre-
viously to bind amyloid fibrils22,23. It is also possible that an
increase in the rate of conversion of pre-nucleation species into
growth competent oligomers, or other steps in the nucleation
process, may also play a role in the enhancement of aggregation.
Spermine was observed to enhance the aggregation of Aβ42 to a
lesser extent than trodusquemine, and its accelerative effect was
not significant under conditions of increased ionic strength.
Trodusquemine, however, was observed to be effective at accel-
erating the aggregation reaction under conditions of moderate
and high ionic strength, indicating that the covalent linkage of
spermine to the sterol ring in trodusquemine is important in its
ability to promote aggregation.
A decrease in the lengths of the fibrils in the presence of tro-
dusquemine was also observed and found to be consistent with
the expectations from the chemical kinetic data. In particular,
increasing the rate of secondary nucleation would be predicted to
shift the reactive flux of the aggregation reaction towards reduced
fibril lengths, just as decreasing the rate of secondary nucleation
with the molecular chaperone Brichos has previously been shown
to increase fibril length15. We note that it has been proposed
previously that enhancing the rate of aggregation alone has the
potential to result in an overall reduction in toxicity by rapidly
converting or consuming low molecular weight oligomers, into
less toxic higher order species, ranging from high molecular
weight aggregates to mature amyloid fibrils10,19,56–59. Indeed, our
results show that the exogenous administration of trodusquemine
reduces Aβ42-mediated toxicity in a C. elegans model of AD in
conjunction with an increase in the rate of in vivo amyloid
accumulation, but without exerting any detectable changes in the
total Aβ42 levels.
An increase in the rate of aggregation that is linked to a
decrease in toxicity has also been observed endogenously in C.
elegans in long-lived daf-2 mutants60 and upon inhibition of the
IGF-1 signaling pathway61. In contrast to the uncontrolled
aggregation that is associated with numerous protein misfolding
diseases, regulated aggregation has been shown to protect the cell
through a variety of mechanisms during ageing and stress62. One
such protective mechanism includes the utilization of specific
highly evolved chaperones to sequester and convert the smallest,
most cytotoxic oligomers into larger aggregates19,47,63. These
strategies are prone to failure, however, as a consequence of the
limited capacity of such systems in the presence of unexpectedly
high levels of aggregation, for example, as a result of ageing or
during the progression of AD47,64. It is possible that trodusque-
mine promotes processes that sequester excess Aβ42 aggregates, a
feature which has been shown to be neuroprotective with mole-
cular chaperones in C. elegans during ageing60.
Confocal microscopy analysis of oligomers of Aβ42 incubated
with human neuroblastoma cells in the presence of trodusque-
mine showed that these oligomers have a diminished affinity for
cell surfaces, a finding that correlates with markedly reduced
levels of toxicity, as a result of the ability of trodusquemine to
bind to cell membranes and displace Aβ42 oligomers. In addition,
a biophysical characterization of the oligomers showed that the
degree of surface hydrophobicity was amplified upon their
interaction with trodusquemine, and such changes in hydro-
phobic solvent exposure were concurrent with increases in
aggregate size. The creation of a more hydrophobic intermediate
aggregate may provide a molecular basis for the promotion of
fibril formation65, as solvent-exposed oligomers can grow to bury
their hydrophobic surfaces within the core of a more ordered
fibril with tighter packing59. The structurally similar aminosterol
squalamine has been shown to interact with phospholipid
bilayers66, and squalamine and trodusquemine have been
observed to displace oligomers of α-synuclein from the cellular
membrane22,23. Consequently, the impact of the induced dis-
placement of oligomeric aggregates from the cell surface is likely
to be very significant, and in addition to play a key role in the
observed suppression of Aβ42 oligomer cytotoxicity.
On the basis of these findings, we suggest that reducing the
toxicity of the oligomeric species by itself could represent a
powerful therapeutic strategy. Indeed, we have observed pre-
viously that aminosterols can decrease the toxicity associated with
protein aggregates, but in that case the rate of α-synuclein
aggregate formation was also reduced22,23. In contrast, our pre-
sent results show that trodusquemine enhances the rate of Aβ42
aggregation in vitro and in a C. elegans model of AD, but
markedly reduces the toxicity caused by aberrant Aβ42 aggregates
in neuronal cells and worms. While trodusquemine attenuates
oligomer binding and toxicity, the increase in aggregation rate is
also consistent with an enhanced conversion of oligomeric species
to mature fibrils, a process that could increase the overall
aggregation rate while reducing the concentration of intermediate
oligomeric species, thus further reducing toxicity. The finding
that trodusquemine suppresses the toxicity caused by Aβ42
aggregation in a C. elegans model of AD when administered both
prior to and after the development of an Aβ42-mediated pheno-
type suggests that trodusquemine, and other molecules that
reduce the toxicity of aggregated species, could be valuable lead
compounds in the search for rational methods of treating AD.
Methods
Chemicals. Trodusquemine was synthesized as a hydrochloride salt at a purity
>97% as measured by mass spectrometry23, stored as a lyophilized powder and
solubilized in water to a final concentration of 10 mM23. Spermine (>97% purity,
Sigma-Aldrich, MO, USA) was solubilized in water to a final concentration of 100
mM. Both molecules were stored in water at −20 °C until use.
Preparation of Aβ42 for chemical kinetics experiments. The recombinant Aβ42
peptide (MDAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA)
was expressed in the Escherichia coli BL21 Gold (DE3) strain (Stratagene, CA,
USA) and purified as described previously9. The purification procedure involved
sonication of the E. coli cells, and a subsequent dissolution of the inclusion bodies
in 8M urea. Ion exchange chromatography was then performed on a diethyl-
aminoethyl cellulose resin, and the protein collected was lyophilized. The lyophi-
lized fractions were further purified using a Superdex 75 26/60 column (GE
healthcare, IL, USA), and the eluates were analysed using SDS-polyacrylamide gel
electrophoresis to detect the presence of the Aβ42 peptide. The fractions containing
the recombinant protein were collected, and subjected to lyophilization again.
Solutions of monomeric protein were prepared by purifying the lyophilized
Aβ42 peptide in 6 M GuHCl. The monomeric protein was purified by gel filtration
in 20 mM sodium phosphate buffer, 200 µM EDTA, pH 8.0 using a Superdex
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75 10/300 column (GE Healthcare) at a flow rate of 0.5 ml/min. In particular,
EDTA was used to chelate any residual metal ions in the buffer, which are known
to affect Aβ aggregation67. ThT was added from a 2mM stock to give a final
concentration of 20 µM. Experiments measuring the effect of spermine and
trodusquemine on the aggregation reaction of Aβ42 at different ionic strengths were
performed in conditions of 5 mM sodium phosphate, 200 µM EDTA, pH 8.0 in the
presence of either 75 or 150 mM NaCl. All samples were prepared in low-binding
Eppendorf tubes and samples were analyzed in a 96-well half area, low-binding,
clear-bottom PEG coated plate (Corning 3881).
For the seeded experiments, pre-formed fibrils were prepared just before the
experiment. Kinetic experiments were set up just as above for a 4 µM Aβ42 sample
in 20 mM sodium phosphate, 200 µM EDTA, pH 8.0, and 20 µM ThT. The ThT
fluorescence was monitored over time to ensure that the fibrils were formed. The
samples were then collected from the wells into low-binding tubes.
Kinetic analysis. ThT fluorescence was monitored in triplicate per sample as
measured using bottom-optics in a plate reader (Fluostar Omega or Fluostar
Optima from BMG Labtech, Aylesbury, UK) with 440 and 480 nm excitation and
emission filters, respectively. Samples were prepared on ice in the absence or
presence of trodusquemine at 0.2, 0.4, and 2 μM. Aggregation was initiated by
transferring the 96-well plate to the plate reader at 37 °C under quiescent condi-
tions. The time evolution of the total fibril mass concentration, M(t), is described
by the following integrated rate law31:
MðtÞ
Mð1Þ ¼ 1
Bþ þ Cþ
Bþ þ Cþeκt
B þ Cþeκt
B þ Cþ
  k21
κ~k1
ek1t ; ð2Þ
where the kinetic parameters B±, C±, κ, k∞ and ~k1 are functions of the two
combinations of the microscopic rate constants k+k2 and k+kn, where kn, k+ and k2
are the primary nucleation, elongation and secondary nucleation rate constants,
respectively. The perturbation induced by trodusquemine can then be resolved by
fitting experimental data to the master equation to identify the alteration(s) of
microscopic process(es), as described in the main text. In particular, we have
performed the in vitro experiments under the buffer conditions described above,
such that we are able to measure accurately and quantitatively the effects of tro-
dusquemine in a well-characterized aggregation system of Aβ429,15,18. The fits were
done using the AmyloFit platform33, which uses a basin-hopping algorithm to find
the best fit to the data. Half-time quantifications were similarly determined using
AmyloFit33.
Atomic force microscopy (AFM). Solutions containing Aβ42 fibrils were depos-
ited on mica positively functionalized with (3-aminopropyl)triethoxysilane
(APTES, Sigma-Aldrich, MO, USA) in the absence of ThT. The incubation time of
4 h was selected as this time was sufficient for all samples to enter the plateau phase
of the chemical kinetics experiments. The mica substrate was positively functio-
nalized prior to sample deposition by the incubation of a 10 μl drop of 0.05% (v/v)
APTES in deionized water (Milli-Q, Merck Millipore, MA, USA) for 1 min at
ambient temperature, rinsed with deionized water and then dried by the passage of
a gentle flow of gaseous nitrogen68. AFM samples were prepared on the freshly
functionalized MICA surfaces by the deposition of a 10 µL drop of protein (2 µM)
for 2 min. Salts were washed away with water and the samples were stored in sealed
containers until imaging was carried out using a JPK Nanowizard2 system (JPK
Instruments, Berlin, Germany) operating in tapping mode with scan rates <0.5 Hz
and a silicon tip with a 10 nm nominal radius (2 Nm−1, Micromasch, Wetzlar,
Germany).
The interaction of the AFM tip with the sample causes changes in its motion.
Whereas, the change in amplitude is related to sample morphology, the change in
phase reflects the dissipated energy during the sample-tip interaction35. The
measurement of each sample at low forces of interaction and constant phase
change, and therefore constant tip-sample interaction, causes low sample
deformation by the tip (<10%)68, and enables us to compare consistently the
morphology of different samples. We thus established standardized experimental
scanning conditions and maintained a regime of phase change on the order of
≈Δ20° upon the interaction of the tip with the sample35. In all, 8–14 high resolution
(1024 by 1024 pixels), phase-controlled images were acquired for each 4 h sample,
for which one representative image is shown in Fig. 2. Three-dimensional maps
were flattened using SPIP (Image Metrology, Hørsholm, Denmark) software, and
lengths were determined by tracing along the median axis of each fibril. Heights
were quantified by determining the cross-sectional diameter of each unique
aggregate35,68. The sensitivity error for the AFM measurements of the height was
calculated as the sum of the instrument electrical noise (<0.05 nm for the JPK
system) and the sample roughness (<0.1 nm), and these errors were added to the
standard error of the mean (SEM) to determine the total error as reported in the
text. A two-sample t-test for means was carried out in OriginPro (OriginLab, MA,
USA) with a test mean value greater than the sensitivity error.
Transmission electron microscopy (TEM). Samples were prepared as described
in the AFM experiments and deposited on a 400-mesh, 3-mm copper grid carbon
support film (EM Resolutions Ltd., Sheffield, UK) and stained with 2% uranyl
acetate (w/v). Salts and excess uranyl acetate were washed by rinsing with deionized
water (Milli-Q). Imaging was carried out on an FEI Tecnai G2 transmission
electron microscope (Cambridge Advanced Imaging Centre, CAIC, University of
Cambridge, UK), and the images were acquired using the SIS Megaview II Image
Capture system (Olympus, Muenster, Germany). Forteen to twenty images were
acquired per 1 h and 4 h samples, for which one representative image is shown in
Fig. 2, and the fibril widths were quantified in ImageJ (NIH, MD, USA) by tracing
the cross-section perpendicular to the fibril axis. In the case of periodicity, the
width of individual fibrils was measured at the crossover point (minimum width of
the fibril) and between the crossovers (maximum width of the fibril), and both
values were included in the final analysis. Fibrils were only quantified if they could
be identified as discrete, individual aggregates (i.e. clustered or ambiguous fibrils
were excluded). Images for quantification were acquired at ×14,500 magnification
corresponding to 0.7 nm per pixel, and the total errors reported in the text were
calculated as the sum of the error associated with the resolution and the SEM. A
two-sample t-test for means was carried out in OriginPro with a test mean value
greater than the sensitivity error.
Nuclear magnetic resonance (NMR) spectroscopy. Uniformly 15N-labeled
recombinantly expressed Aβ42 (rPeptide, GA, USA) was prepared following the
manufacturer’s instructions and stored at −80 °C until use. Samples were prepared
using 50 µM protein in the absence and presence of 50 µM trodusquemine (5 mM
sodium phosphate, pH 7.5). While trodusquemine is highly soluble in water, its
solubility in 5 mM sodium phosphate is limited above 50 µM. Eight scans were
taken for each spectrum using a 500MHz NMR (Bruker) at 5 °C, and the
assignments were obtained from previous spectra69.
Preparation of oligomers. Lyophilized Aβ42 (Sigma-Aldrich, MO, USA) was
dissolved in 100% hexafluoro-2-isopropanol (HFIP) to 1.0 mM and then the sol-
vent was evaporated. Aβ-derived diffusible ligands (ADDLs) were prepared from
Aβ42 solutions according to Lambert’s protocol41 and analysed using western
blotting and a dot blot assay to ensure they were closely similar to those previously
reported41. Western blotting was performed by separating 2.25 µg of ADDLs on a
4–12% criterion XT Precast Bis-Tris gel probed with 1:800 mouse monoclonal
6E10 antibodies (803001, BioLegend, CA, USA) and 1:3000 peroxidase-conjugated
anti-mouse secondary antibodies (AB6728, Abcam, Cambridge, UK). Dot blots
were carried out by spotting 2 µl of monomers, ADDLs and fibrils (1 µg in
monomer equivalents) and probing with 1:500 human anti-ADDLs therapeutic
antibody (clone 19.3, TAB-0813CLV, Creative Biolabs, NY, USA) or with 1:800
mouse monoclonal 6E10 antibodies and then with 1:1000 peroxidase-conjugated
anti-human secondary antibodies (A0170, Sigma-Aldrich, MO, USA) or with
1:3000 peroxidase-conjugated anti-mouse secondary antibodies.
Neuroblastoma cell cultures. Human SH-SY5Y neuroblastoma cells (Sigma-
Aldrich, MO, USA, origin from A.T.C.C., VA, USA) were cultured in DMEM, F-12
HAM with 25 mM HEPES and NaHCO3 (1:1) and supplemented with 10% FBS, 1
mM glutamine and 1.0% antibiotics. Cell cultures were maintained in a 5% CO2
humidified atmosphere at 37 °C and grown until they reached 80% confluence for a
maximum of 20 passages46,70. The cell line was authenticated by the European
Collection of Authenticated Cell Cultures using short tandem repeat loci analyses
and tested negative for mycoplasma contaminations.
MTT reduction assay. Cell viability was assessed by means of the 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay46. Aβ42
oligomers (1 µM monomer equivalents), prepared according to Lambert’s proto-
col41, were incubated with or without increasing concentrations (0.1, 0.33 and 1
µM) of trodusquemine for 1 h at 37 °C under shaking conditions, and then added
to the cell culture medium of SH-SY5Y cells seeded in 96-well plates for 24 h. The
Aβ42-to-trodusquemine molar ratios used here were 10:1, 3:1, 1:1 for TRO. Samples
were distributed throughout the mutliwell plate using a random allocation
approach. Following 24 h, the cells were incubated with 0.5 mg/ml MTT at 37 °C
for 4 h, and with cell lysis buffer (20% SDS, 50% N,N-dimethylformamide, pH 4.7)
for 3 h. The absorbance values of blue formazan were determined at 590 nm. Cell
viability was expressed as the percentage of MTT reduction in treated cells as
compared to untreated cells. Pre-treatment experiments were carried out by
incubating the cells for 15 min with 1 µM trodusquemine, after which time they
were washed with PBS and subsequently exposed to oligomers for 24 h.
Measurement of intracellular ROS. Aβ42 oligomers (1 µM monomer equivalents)
were added to the cell culture medium of SH-SY5Y cells seeded on glass coverslips
for 15 min, in the absence or presence of 1 µM trodusquemine. To detect intra-
cellular ROS production, cells were then loaded with 10 µM 2′,7′-dichlorodihy-
drofluorescein diacetate (CM-H2DCFDA, Life Technologies, CA, USA)70. Pre-
treatment experiments were carried out by incubating the cells for 15 min with 1
µM trodusquemine, after which time they were washed with PBS and subsequently
exposed to oligomers for 15 min. Cells were labeled with the CM-H2DCFDA probe
in the last 10 min of treatment, and the resulting fluorescence was analyzed by a
TCS SP5 scanning confocal microscopy system (Leica Microsystems, Mannheim,
Germany) equipped with an argon laser source, using the 488 nm excitation line. A
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series of 1.0 µm thick optical sections (1024 × 1024 pixels) were taken through the
cells for each sample using a Leica Plan Apo ×63 oil immersion objective (Leica
Microsystems, Mannheim, Germany) and then projected as a single composite
image by superimposition. The confocal microscope was set at optimal acquisition
conditions, e.g., pinhole diameters, detector gain and laser powers. Settings were
maintained constant for each analysis.
Oligomer binding to the cellular membrane. SH-SY5Y cells were seeded on glass
coverslips and treated for 15 min with Aβ42 oligomers (1 µM monomer equiva-
lents) in the absence or presence of 1 µM trodusquemine. Pre-treatment experi-
ments were carried out by incubating the cells for 15 min with 1 µM
trodusquemine, after which time they were washed with PBS and subsequently
exposed to oligomers for 15 min. After incubation, the cells were washed with PBS
and counterstained with 5.0 µg/ml Alexa Fluor 633-conjugated wheat germ
agglutinin (Life Technologies, CA, USA)22. After washing with PBS, the cells were
fixed in 2% (w/v) buffered paraformaldehyde for 10 min at room temperature
(RT, 20 °C). The presence of oligomers was detected with 1:800 diluted mouse
monoclonal 6E10 anti-Aβ antibodies (BioLegend, CA, USA) and subsequently with
1:1000 diluted Alexa Fluor 488-conjugated anti-mouse secondary antibodies (Life
Technologies, CA, USA). To detect only the oligomers bound to the cell surface,
the cellular membrane was not permeabilized at this stage, thus preventing anti-
body internalization. The median planes of the cells were also analyzed to exclude
the possibility that the green fluorescence arises from the cytosol. Fluorescence
emission was detected after double excitation at 488 nm and 633 nm by the
scanning confocal microscopy system described above, and three apical sections
were projected as a single composite image by superimposition. Binding histo-
grams were created using ImageJ (NIH, MD, USA) and JACOP plugin (rsb.info.
nih.gov) software.
Analysis of oligomer co-localization with lysosomes. SH-SY5Y cells were
treated for 15 min with 1 μM ADDLs formed from HiLyte™ Fluor 647-labeled
Aβ42 (AnaSpec, CA, USA), washed with PBS and labelled with 50 nM of the
LysoTracker® Green DND-26 probe (Thermo Fisher Scientific, Waltham, MA,
USA) for 30 min. Untreated or chloroquine-treated (50 μM, 4 h) cells were used as
negative and positive controls. The lysosomes and the oligomers were detected by
using double excitation at 488 nm and 647 nm.
ANS binding measurements. Aβ42 oligomers (5 µM monomer equivalents) were
incubated in the absence or presence of 5, 12.5, 25, 37.5 and 50 µM concentrations
of trodusquemine in 20 mM Tris, 100 mM NaCl for 1 h at 20 °C. 8-anilino-1-
naphthalenesulfonate (ANS, Sigma-Aldrich, MO, USA) was then added to a final
concentration of 15 µM. Fluorescence emission spectra were recorded using a plate
reader (BMG Labtech, Aylesbury, UK) with excitation at 380 nm. Representative
data are shown in Fig. 4 for three-independent experiments.
Light scattering. Samples were prepared as described above, but in the absence of
ANS. Static light scattering measurements were performed at 25 °C using the
Malvern Zetasizer Nano S instrument (Malvern, Worcestershire, UK) with fixed
parameters (attenuator 10, cell position 4.65 mm), equipped with a Peltier tem-
perature controller. A low volume (100 µl) disposable cuvette was used (BRAND,
Wertheim, Germany).
C. elegans strains. All strains of C. elegans were acquired from the Caenorhabditis
Genetics Center (CGC), which is funded by National Institutes of Health Office of
Research Infrastructure Programs (P40 OD010440). Two strains were utilized for
these experiments. The temperature sensitive human amyloid beta expressing
strain dvIs100 [unc-54p::A-beta-1–42::unc-54 3′-UTR+mtl-2p::GFP] (GMC101)
was used, in which mtl-2p::GFP causes intestinal GFP expression and unc-54p::A-
beta-1–42 expresses the human full-length Aβ42 in the muscle cells of the body
wall. Raising the temperature above 20 °C at the L4 or adult stage causes paralysis
due to Aβ42 aggregation in the body wall muscle. The N2 strain was used for wild-
type worms.
C. elegans media. Standard conditions were used for the propagation of C. ele-
gans71. Briefly, the animals were synchronized by hypochlorite bleaching and
subsequently hatched overnight in M9 buffer (3 g/l KH2PO4, 6 g/l Na2HPO4, 5 g/l
NaCl, 1 µM MgSO4), after which they were cultured at 20 °C on nematode growth
medium (NGM) (CaCl2 1 mM, MgSO4 1 mM, cholesterol 5 µg/ml, 250 µM
KH2PO4 pH 6, agar 17 g/L, NaCl 3 g/l, casein 7.5 g/l) plates seeded with the E. coli
strain OP50. Saturated cultures of OP50 were grown by inoculating 50 mL of LB
medium (tryptone 10 g/l, NaCl 10 g/l, yeast extract 5 g/l) with OP50 and incubating
the culture for 16 h at 37 °C. NGM plates were seeded with bacteria by adding 350
µl of saturated OP50 to each plate and leaving the plates at 20 °C for 2–3 days. On
day 3 after synchronization, the animals were placed on NGM plates containing
5-fluoro-2′-deoxyuridine (FUdR, Sigma-Aldrich, MO, USA) (75 µM) to inhibit the
growth of offspring and stored for the duration of their lifespan at 24 °C.
Trodusquemine administration to C. elegans. NGM plates containing FUdR
were seeded with 2.2 ml aliquots of trodusquemine at the appropriate con-
centration or water as the vehicle and dried in a laminar flow hood at RT. Worms
were transferred by random allocation to plates coated with trodusquemine or
water at the L4 stage of development or D6. Worms treated with trodusquemine
at D6 were maintained on FUdR plates from the L4 stage of development at
24 °C, as described above.
Automated C. elegans phenotypic assay. At the times indicated and for each
condition, worms were washed off the plates with M9 buffer and spread over an
OP50 unseeded 9 cm NGM plate in a final volume of 5 mL, after which their
movements were recorded at 20 fps using a recently developed microscopic pro-
cedure for 60 s22,54. The sample size was determined based on previous studies8,22.
Videos were analyzed in a consistent manner to track worm motility (bends per
minute), speed of swimming and the extent of paralysis; paralyzed worms were
defined by the code as being those which move less than 5 bends per min-
ute and with a swimming speed of less than 1 mm/min. Further details regarding
the hardware of the tracker and its associated code are available from 54 and from
the authors. All data shown are representative of three experiments from individual
developmentally synchronized populations of worms.
NIAD-4 staining of live C. elegans. Live animals were incubated with NIAD-4
over a range of concentrations and times, and it was empirically determined that
incubation of living animals with 1 μM NIAD-4 (0.1% DMSO in M9 buffer) for 4 h
at room temperature gave robust and reproducible staining. After staining, animals
were allowed to recover on NGM plates for about 24 h to allow destaining via
normal metabolism. Stained animals were mounted on 2% agarose pads containing
40 mM NaN3 as anaesthetic on glass microscope slides for imaging8. Images were
captured with a Zeiss Axio Observer A1 fluorescence microscope (Carl Zeiss
Microscopy GmbH, Jena, Germany) with a ×20 objective and a 49004 ET-CY3/
TRITC filter (Chroma Technology Corp, VT, USA). Fluorescence intensity was
calculated using ImageJ software (NIH, MD, USA) and then normalized as the
corrected total cell fluorescence. Only the head region was considered because of
the high background signal in the guts. All experiments were carried out in tri-
plicate, and the data from one representative experiment are shown. Twenty ani-
mals were analyzed per condition. The representative images shown in Fig. 5a have
been uniformly modified by the ‘fire’ filter in ImageJ to facilitate the visualization of
the aggregates.
C. elegans immunoblots. Animals were prepared and treated with trodusque-
mine from the L4 stage of development as described above. At D5 of adulthood,
~6000 worms per condition were collected from FUdR plates and samples were
extracted by sonication in 8 M urea, 2% SDS, 50 mM DTT, 50 mM Tris, pH 8.0
with 1X proteinase inhibitor cocktail (Roche, Mannheim, Germany). Lysates of
each sample were combined with NuPAGE LDS sample buffer (1X) and NuPAGE
sample reducing agent (1X) (Life Technologies, CA, USA) and heated for 10 min
at 70 °C. Samples were separated using a NuPAGE Novex 4–12% Bis-Tris Protein
gel (Life Technologies, CA, USA). Gels were incubated for 10 min at RT in 10%
ethanol prior to transferring to a nitrocellulose membrane (iBlot Dry Blotting
System, Life Technologies, CA, USA). Membranes were cut and incubated at 4 °C
overnight with 1:1000 monoclonal anti-α-tubulin antibodies (clone B-5-1-2,
T5168, Sigma-Aldrich, MO, USA) and the bottom section was incubated with
1:1500 monoclonal anti-Aβ antibodies (clone W0-2, MABN10, Merck Millipore,
MA, USA). 1:5000 Alexa 488-conjugated secondary antibody (anti-mouse, Life
Technologies, CA, USA) was incubated for 1 h at RT, and membranes were
measured for fluorescence using a Typhoon Trio Imager (GE Healthcare, IL,
USA). Monomeric Aβ42 was prepared as described above and used as a positive
control. The lysate of control worms not expressing Aβ42 was used as a negative
control. Lysates were run in triplicate and band intensities were quantified in
ImageJ (NIH, Bethesda, MD) using gel analysis. Data shown are representative of
duplicate experiments that gave consistent results. Uncropped blots are shown in
Supplementary Figure 13.
Statistical analysis. Except where otherwise stated, comparisons between the
different groups were performed by one-way ANOVA followed by Bonferroni’s
post comparison test and the unpaired, two-tailed Student’s t-test, and all statistical
tests were performed in GraphPad Prism 7.0 (CA, USA). P < 0.05 was accepted as
statistically significant.
Data availability
Data supporting the findings of this manuscript are available from the corre-
sponding authors upon reasonable request.
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